Eptifibatide

Identification

Name
Eptifibatide
Accession Number
DB00063 / NA8320J834
Groups
Eptifibatide
Description

artificial cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.

Pharmacology

Pharmacodynamics

Eptifibatide is an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarus barbouri). It belongs to the class of the so called arginin-glycin-aspartat-mimetics and reversibly binds to platelets.

Indication

For treatment of myocardial infarction and acute coronary syndrome.

Action

Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.